Voluntary nationwide recall: Exela Pharma (October)
Nov. 2023Pharmacy Updates
"Exela Pharma Sciences, LLC (Exela) is recalling several lots of 8.4% Sodium Bicarbonate Injection, USP. This drug is used for the treatment of metabolic acidosis (a buildup of acid in the body).
This drug (NDC: 51754-5001-04) is being recalled because routine inspection of samples found particles of silicone. Administration of an injectable product that contains particulate matter may result in local irritation or swelling in response to the foreign material. If the particulate matter reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs, or brain. The blockage can cause stroke and even lead to death. Read the full text of the Excela Pharma recall."
Recent Announcements
Voluntary nationwide recall: Atorvastatin (Alkem – October)
Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.Nov. 2025Pharmacy Updates
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates